<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01599442</url>
  </required_header>
  <id_info>
    <org_study_id>August-1</org_study_id>
    <nct_id>NCT01599442</nct_id>
  </id_info>
  <brief_title>Register for Patients With Diabetic Foot Syndrome and Critical Limb Ischemia</brief_title>
  <acronym>August-1</acronym>
  <official_title>Register for Patients With Diabetic Foot Syndrome and Critical Limb Ischemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GWT-TUD GmbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diabetic foot syndrome (DFS) is a disease caused by neurogenic (concerning the nervous&#xD;
      system), vascular, mechanic and metabolic factors, which are further complicated by an&#xD;
      impairment of the immune system and a corresponding increase in the risk for infections.&#xD;
      Results from clinical trials about the efficacy of interventions aimed at reducing the number&#xD;
      of patient-relevant end points are of limited comparability due to the heterogenity of&#xD;
      patient characteristics. By their very nature, randomized clinical trials (RCT) can only&#xD;
      focus on a limited section of the wide range of possible intervention regimes. In clinical&#xD;
      practice, however, a number of patients with dfs will never have been part of a clinical&#xD;
      trial. Furthermore, there are only very few contemporary registers for this indication from&#xD;
      which conclusions with regard to the comparative merits of different therapeutic strategies&#xD;
      may be drawn.&#xD;
&#xD;
      The register was conceived to find out to which extent RCT patients are representative for&#xD;
      the overall patient collective with dfs and critical limb ischemia and to evaluate the&#xD;
      therapeutic success of other treatment strategies. An RCT to assess the efficacy of urokinase&#xD;
      versus placebo is imbedded in the register.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      August-1 is a register to find out to which extent RCT patients are representative for the&#xD;
      overall patient collective with dfs and critical limb ischemia and to evaluate the&#xD;
      therapeutic success of other treatment strategies. An RCT to assess the efficacy of urokinase&#xD;
      versus placebo is imbedded in the register.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recrution number was not reached&#xD;
  </why_stopped>
  <start_date>June 2010</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>duration of survival without major amputation</measure>
    <time_frame>to be assessed after 12 months observation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>major amputation</measure>
    <time_frame>after 12 months observation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>total mortality</measure>
    <time_frame>after 12 months observation</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">123</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Diabetic Foot</condition>
  <condition>Critical Limb Ischemia</condition>
  <eligibility>
    <study_pop>
      <textblock>
        outpatients from hospitals with a department specializing in the treatment of diabetic foot&#xD;
        syndrome&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diabetic patients with dfs and critical limb ischemia&#xD;
&#xD;
          -  age 18 and older&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  less than 1 year life expectancy&#xD;
&#xD;
          -  prior major amputation&#xD;
&#xD;
          -  planned major expectation&#xD;
&#xD;
          -  prior treatment of the current episode of dfs with urokinase&#xD;
&#xD;
          -  mechanical heart valve replacement&#xD;
&#xD;
          -  cerebral event with changes in CT during the last three months&#xD;
&#xD;
          -  non-remediated proliferating retinopathy&#xD;
&#xD;
          -  uncontrolled hypertension (systolic &gt; 180 mmHg, diastolic &gt; 100 mmHg)&#xD;
&#xD;
          -  hemorrhagic diathesis (spontaneous quick value &lt; 50%, spontaneous ptt &gt; 40 sec,&#xD;
             thrombocytes &lt; 100 gpt/l)&#xD;
&#xD;
          -  acute gastrointestinal bleeding or ulcers during the last 4 weeks&#xD;
&#xD;
          -  prior reverse bypass operation&#xD;
&#xD;
          -  concomitant participation in other clinical trials&#xD;
&#xD;
          -  insufficient compliance&#xD;
&#xD;
          -  premenopausal women not using a safe method of contraception (i. e. IUD, hormone&#xD;
             implants, hormone depot injection, combined pill (estrogens and gestagens), vaginal&#xD;
             ring or vasectomized partner).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>S. Schellong, Prof.Dr.med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Staedt. KH Dresden-Friedrichstadt</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Krankenhaus Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <state>Sachse</state>
        <zip>01076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>May 14, 2012</study_first_submitted>
  <study_first_submitted_qc>May 15, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 16, 2012</study_first_posted>
  <last_update_submitted>April 4, 2014</last_update_submitted>
  <last_update_submitted_qc>April 4, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

